Scarica l'app Stockscreener
11.73
2.82%
-0.34
Dopo l'orario di chiusura:
11.50
-0.23
-1.96%
Precedente Chiudi:
$12.07
Aprire:
$12.04
Volume 24 ore:
1.13M
Relative Volume:
1.42
Capitalizzazione di mercato:
$641.39M
Reddito:
$27.46M
Utile/perdita netta:
$-46.05M
Rapporto P/E:
-9.093
EPS:
-1.29
Flusso di cassa netto:
$-33.83M
1 W Prestazione:
-8.29%
1M Prestazione:
+29.76%
6M Prestazione:
+43.93%
1 anno Prestazione:
+93.88%
Intervallo 1D:
$11.64
$12.21
Intervallo di 1 settimana:
$11.64
$13.16
Portata 52W:
$5.45
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Nome
Zevra Therapeutics Inc
Settore
Industria
Telefono
(321) 939-3416
Indirizzo
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Confronta ZVRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
11.73 | 699.35M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-02 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-08 | Ripresa | Cantor Fitzgerald | Overweight |
| 2024-10-07 | Iniziato | Guggenheim | Buy |
| 2024-09-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-09-24 | Reiterato | Maxim Group | Buy |
| 2024-04-02 | Reiterato | Maxim Group | Buy |
| 2024-03-12 | Iniziato | William Blair | Outperform |
| 2023-03-17 | Iniziato | Maxim Group | Buy |
Mostra tutto
Zevra Therapeutics Inc Borsa (ZVRA) Ultime notizie
What analysts say about Zevra Therapeutics Inc. stockConsistently high returns - Autocar Professional
What drives Zevra Therapeutics Inc. stock priceExceptional financial outcomes - Autocar Professional
Zevra Therapeutics Inc. Stock Analysis and ForecastFree Investment Timing Strategies - jammulinksnews.com
Is Zevra Therapeutics Inc. a good long term investmentRapid wealth multiplication - jammulinksnews.com
Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® - GlobeNewswire
Zevra Therapeutics: Promising Growth Driven by Miplyffa Success and Strategic Focus on Rare Diseases - TipRanks
ZVRA Showcases Key Findings on MIPLYFFA and OLPRUVA at Genetics - GuruFocus
Zevra Therapeutics Highlights Research on MIPLYFFA® and OLPRUVA® at 42nd Annual SERGG Meeting - Nasdaq
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail
William Blair Issues Optimistic Forecast for ZVRA Earnings - Defense World
Zevra Therapeutics' MIPLYFFA: A Paradigm Shift in Rare Disease Treatment - AInvest
Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great Choice - Yahoo Finance
5 Small Drug Stocks To Buy Amid Trump's New Tariff Threats - Barchart.com
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats - The Globe and Mail
Zevra Therapeutics Publishes Long-Term Efficacy and Safety Results for MIPLYFFA in Niemann-Pick Disease Type C - Nasdaq
Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism - The Manila Times
Breakthrough: New Clinical Data Shows MIPLYFFA Halts Rare Brain Disease Progression for 5 Years - Stock Titan
Niemann-Pick Disease Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Treatment, Therapies and Companies by DelveInsight - The Globe and Mail
ZVRA Publishes Positive Long-term Results for Arimoclomol in NPC Treatment | ZVRA Stock News - GuruFocus
Why Zevra Therapeutics Inc. stock attracts strong analyst attentionEarly Buy Suggestion - newser.com
What makes Zevra Therapeutics Inc. stock price move sharplyHigh Yield Stock Selection - Newser
Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know - Yahoo Finance
Here's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA) - Yahoo Finance
How Zevra Therapeutics Inc. stock performs during market volatilityBreakout Momentum Alerts - Newser
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Cantor Fitzgerald Issues Positive Outlook for ZVRA Earnings - Defense World
Cantor Fitzgerald Forecasts Strong Price Appreciation for Zevra Therapeutics (NASDAQ:ZVRA) Stock - Defense World
Zevra Therapeutics (NASDAQ:ZVRA) Upgraded to Strong-Buy at Wall Street Zen - Defense World
Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) - GlobeNewswire
Zevra(ZVRA) Soars 4.41% on Phase 2 Trial, Strategic Collaboration - AInvest
ZVRA Highlights MIPLYFFA Data at Niemann Pick Conference | ZVRA Stock News - GuruFocus
Zevra Therapeutics Announces MIPLYFFA® (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference | ZVRA Stock News - GuruFocus
Zevra Therapeutics Showcases MIPLYFFA® Data at National Niemann Pick Disease Foundation Conference - Nasdaq
Zevra Therapeutics presents MIPLYFFA data at NNPDF Conference, FDA-approved NPC treatment. - AInvest
MIPLYFFA Clinical Data Shows Disease-Halting Results for Niemann-Pick Disease | ZVRA Stock News - Stock Titan
Analysts Offer Insights on Healthcare Companies: Zevra Therapeutics (ZVRA), Exact Sciences (EXAS) and GH Research (GHRS) - The Globe and Mail
(ZVRA) Trading Report - news.stocktradersdaily.com
Zevra Therapeutics shares rise 2.33% after-hours amid AI-driven market optimism. - AInvest
Cantor Fitzgerald raises Zevra Therapeutics stock price target to $29 on NPC drug progress By Investing.com - Investing.com South Africa
Cantor Fitzgerald raises Zevra Therapeutics stock price target to $29 on NPC drug progress - Investing.com Nigeria
ZVRA: Zevra Therapeutics Receives Raised Price Target by Analyst - GuruFocus
Zevra Therapeutics Inc Azioni (ZVRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):